Search company, investor...

Ceptur Therapeutics

cepturtx.com

Founded Year

2013

Stage

Series A | Alive

Total Raised

$81.28M

Last Raised

$75M | 10 mos ago

About Ceptur Therapeutics

Ceptur Therapeutics, fka Silagene, is a pre-clinical stage biotechnology company focused on developing targeted oligonucleotide therapeutics based on U1 Adaptor technology.

Headquarters Location

1 Ilene Ct, Building 8 Unit 9

Hillsborough, New Jersey, 08844,

United States

Missing: Ceptur Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Ceptur Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Ceptur Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ceptur Therapeutics is included in 4 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

M

Medical Devices

8,560 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,901 items

Ceptur Therapeutics Patents

Ceptur Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/31/2014

9/13/2016

Molecular biology, Genetics, Gene expression, Biotechnology, Molecular biology techniques

Grant

Application Date

10/31/2014

Grant Date

9/13/2016

Title

Related Topics

Molecular biology, Genetics, Gene expression, Biotechnology, Molecular biology techniques

Status

Grant

Latest Ceptur Therapeutics News

11:30 EDT New Therapeutics Options in Huntington's Disease Pipeline as 45+ Key Companies are Working on Drug Profiles | DelveIns...

Oct 24, 2022

| DelveInsight News provided by Share this article Share this article Huntington's Disease pipeline constitutes 45+ key companies continuously working towards developing 50+ Huntington's Disease treatment therapies, analyzes DelveInsight LAS VEGAS, Oct. 24, 2022 /PRNewswire/ -- DelveInsight's ' Huntington's Disease Pipeline Insight – 2022 ' report provides comprehensive global coverage of available, marketed, and pipeline Huntington's disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Huntington's disease pipeline domain. Key Takeaways from the Huntington's Disease Pipeline Report DelveInsight's Huntington's disease pipeline report depicts a robust space with 45+ active players working to develop 50 + pipeline therapies for Huntington's disease treatment. Key Huntington's disease companies such as Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, SAGE Therapeutics, PTC Therapeutics, WaVe life Sciences, Novartis, Neurimmune Therapeutics, SOLA Biosciences, UniQure Biopharma, Roche, Annexon, Inc., Azevan Pharmaceuticals, SOM Innovation Biotech SA, Asklepios BioPharmaceutical, Luye Pharma Group Ltd., BrainStorm Cell Therapeutics, Voyager Therapeutics, Passage Bio, Locana Bio, Ceptur Therapeutics, Enzerna Biosciences, AFFiRiS AG, Arvinas, Atalanta Therapeutics, Anima Biotech, and others are evaluating novel Huntington's disease treatment drugs candidate to improve the treatment landscape. Promising Huntington's disease pipeline therapies in various stages of development include Pridopidine, Tominersen, ANX-005, Pepinemab, Valbenazine, SAGE-718, PTC-518, WVE-003, AMT 130, Branaplam, NI-302, SOL-176, RO7234292, ANX005, SRX246, Bevantolol, SOM3355, BV-101 Gene Therapy, LPM3770164, Passage Bio Research Project, Huntington disease Research Project, BrainStorm Research Project, Locana Huntington disease Research Project,  Ceptur Huntington Research Project, HTT RNA Research project, mHTT Research Project, AFFiRiS Huntington Research Project, HTT Research Project, Anima Biotech mHTT Research Project, and others. In August 2022, Asklepios BioPharmaceutical, a wholly owned and independently operated subsidiary of Bayer AG,  received clearance to conduct a Phase I/II trial for its novel Huntington's Disease (HD) gene therapy, BV-101, in France through its subsidiary BrainVectis. This authorization, provided by the National Agency for Safety of Medicines and Health Products (ANSM), the country's governing drug authority, along with the approval of the trial protocol by the Ethics Committee in charge, enables the company to begin recruiting participants In March 2022, PTC Therapeutics announced the initiation of the PIVOT-HD Phase  II clinical trial evaluating PTC518 in people with Huntington's disease (HD). PIVOT-HD is a global trial starting in the United States. PTC518 is an oral, small molecule splicing modifier that was specifically designed to lower huntingtin mRNA and protein selectively. There are no current treatments for the underlying cause of HD In January 2022, Ionis Pharmaceuticals announced that its partner Roche is designing a new Phase II trial to evaluate tominersen in Huntington's disease (HD). After halting dosing in the Phase III GENERATION HD1 study, exploratory posthoc analyses suggest tominersen may benefit younger adult patients with lower disease burden. These results require confirmation in a randomized, placebo-controlled study In September 2021, Sage Therapeutics announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to SAGE-718 for development as a potential treatment for Huntington's disease (HD). In September 2021, Voyager Therapeutics introduced new programs in Huntington's disease, a monogenic form of ALS (SOD1), spinal muscular atrophy, and diseases linked to GBA1 mutations, all powered by its proprietary AAV capsids that have demonstrated superior transgene expression in the brain compared to AAV9 delivery in non-human primates. Request a sample and discover the recent advances in Huntington's disease treatment @ Huntington's Disease Pipeline Report The Huntington's disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Huntington's disease products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Huntington's disease pipeline landscape. Huntington's Disease Overview Huntington's disease is a rare, inherited disease that causes the progressive breakdown (degeneration) of brain nerve cells. It's an autosomal dominant condition caused by a single faulty gene on chromosome 4. The common symptoms of Huntington's disease include involuntary jerking or writhing movements (chorea), muscle problems such as rigidity or muscle contracture (dystonia), slow or abnormal eye movements, impaired balance, difficulty speaking or swallowing, difficulty organizing, prioritizing, or focusing on tasks, and fatigue and loss of energy. A general physical examination, medical history, and thorough neurological and psychiatric examinations are used for Huntington's disease diagnosis. Huntington's disease treatment focuses on symptom management, which includes medications and psychotherapy. Tetrabenazine (Xenazine) and deutetrabenazine (Austedo) have been specifically approved by the FDA to suppress Huntington's disease-related involuntary jerking and writhing movements (chorea). A snapshot of the Huntington's Disease Pipeline Drugs mentioned in the report: Drugs Huntington's Disease Therapeutics Assessment The  Huntington's disease pipeline  report proffers an integral view of Huntington's disease emerging novel therapies segmented by stage, product type,  molecule type,  mechanism of action, and route of administration. Scope of the Huntington's Disease Pipeline Report  Coverage: Global  Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration:  Oral, Parenteral, Intravitreal, Subretinal, Topical Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy Therapeutics Assessment By Mechanism of Action: Dopamine D2 receptor antagonists, Glutamate modulators, Sigma-1 receptor agonists, HD protein inhibitors, RNA interference, Complement C1 inhibitors, CD100 antigen inhibitors, Vesicular monoamine transporter 2 inhibitors, P38 mitogen-activated protein kinase inhibitors, NMDA receptor modulators Key Huntington's Disease Companies: Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, SAGE Therapeutics, PTC Therapeutics, WaVe life Sciences, Novartis, Neurimmune Therapeutics, SOLA Biosciences, UniQure Biopharma, Roche, Annexon, Inc., Azevan Pharmaceuticals, SOM Innovation Biotech SA, Asklepios BioPharmaceutical, Luye Pharma Group Ltd., BrainStorm Cell Therapeutics, Voyager Therapeutics, Passage Bio, Locana Bio, Ceptur Therapeutics, Enzerna Biosciences, AFFiRiS AG, Arvinas, Atalanta Therapeutics, Anima Biotech, and others Key Huntington's Disease Pipeline Therapies: Pridopidine, Tominersen, ANX-005, Pepinemab, Valbenazine, SAGE-718, PTC-518, WVE-003, AMT 130, Branaplam, NI-302, SOL-176, RO7234292, ANX005, SRX246, Bevantolol, SOM3355, BV-101 Gene Therapy, LPM3770164, Passage Bio Research Project, Huntington disease Research Project, BrainStorm Research Project, Locana Huntington disease Research Project,  Ceptur Huntington Research Project, HTT RNA Research project, mHTT Research Project, AFFiRiS Huntington Research Project, HTT Research Project, Anima Biotech mHTT Research Project, and others. Dive deep into rich insights for FDA-approved drugs for Huntington's disease, visit @ Huntington's Disease Drugs Table of Contents

Ceptur Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ceptur Therapeutics Rank

Ceptur Therapeutics Frequently Asked Questions (FAQ)

  • When was Ceptur Therapeutics founded?

    Ceptur Therapeutics was founded in 2013.

  • Where is Ceptur Therapeutics's headquarters?

    Ceptur Therapeutics's headquarters is located at 1 Ilene Ct, Building 8, Hillsborough.

  • What is Ceptur Therapeutics's latest funding round?

    Ceptur Therapeutics's latest funding round is Series A.

  • How much did Ceptur Therapeutics raise?

    Ceptur Therapeutics raised a total of $81.28M.

  • Who are the investors of Ceptur Therapeutics?

    Investors of Ceptur Therapeutics include Affinity Asset Management, Qiming Venture Partners, Bristol-Myers Squibb, venBIO, Boxer Capital and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.